Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

Delia Mulas, Patrizio Pasqualetti, Paolo Maria Rossini, D. Landi, S. Vollaro, G. Pellegrino, D. Mulas, A. Ghazaryan, E. Falato, P. Pasqualetti, P. M. Rossini, M. M. Filippi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

22 Citazioni (Scopus)

Abstract

Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.
Lingua originaleEnglish
pagine (da-a)165-169
Numero di pagine5
RivistaClinical Neurophysiology
Volume126
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Administration, Oral
  • Adult
  • Animals
  • Evoked Potentials, Motor
  • Female
  • Fingolimod
  • Fingolimod Hydrochloride
  • Glutamate
  • Glutamic Acid
  • Humans
  • Immunosuppressive Agents
  • Intracortical facilitation
  • Male
  • Middle Aged
  • Motor Cortex
  • Motor cortex
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple sclerosis
  • Propylene Glycols
  • Prospective Studies
  • Sphingosine
  • Transcranial Magnetic Stimulation
  • Transcranial magnetic stimulation

Fingerprint

Entra nei temi di ricerca di 'Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis'. Insieme formano una fingerprint unica.

Cita questo